NCT04786158View on ClinicalTrials.gov

Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

June 1, 2020

Study Completion Date

July 1, 2020

Conditions
Progressive Supranuclear PalsyCorticobasal Degeneration
Interventions
DRUG

Apomorphine

Reporting the effects of subcutaneous apomorphine on pain and on quality of life

Trial Locations (1)

75019

Hôpital Fondation Adolphe de Rothschild, Paris

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT04786158 - Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) | Biotech Hunter | Biotech Hunter